X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding CIN-107 (baxdrostat), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,800.0 million Upfront Cash: $1,300.0 million
Deal Type: Acquisition February 24, 2023
Details:
CIN-107 (baxdrostat) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient with treatment-resistant hypertension and primary aldosteronism.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, CIN-107 (baxdrostat), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,800.0 million Upfront Cash: $1,300.0 million
Deal Type: Acquisition January 09, 2023
Details:
Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, for the treatment-resistant hypertension and primary aldosteronism.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Baxdrostat (CIN-107) is a highly selective, once-daily, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for treatment-resistant hypertension and primary aldosteronism.
Lead Product(s): Baxdrostat
Therapeutic Area: Nephrology Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 11, 2022
Details:
Baxdrostat (CIN-107), is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for the synthesis of aldosterone in adrenal gland, in development for patient populations with significant unmet medical needs.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
CIN-107 (Baxdrostat) is highly selective aldosterone synthase inhibitor that significantly reduce aldosterone levels, offering potential to not only improve uncontrolled blood pressure in CKD patients, but also ameliorate negative impacts of aldosterone on kidney function.
Lead Product(s): Baxdrostat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CIN-107
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
